Universität zu Köln

Boell, Boris, Bredenfeld, Henning, Goergen, Helen, Halbsguth, Teresa, Eich, Hans T., Soekler, Martin, Markova, Jana, Keller, Ulrich, Graeven, Ullrich, Kremers, Stephan, Geissler, Michael, Trenn, Guido, Fuchs, Michael, von Tresckow, Bastian, Eichenauer, Dennis A., Borchmann, Peter and Engert, Andreas (2011). Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood, 118 (24). S. 6292 - 6299. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

Approximately 20% of all Hodgkin lymphoma (HL) patients are older than 60 years and have a poor prognosis, mainly because of increased treatment-related toxicity resulting in reduced overall dose intensity and more treatment-related mortality. To possibly improve the treatment of elderly HL patients, the German Hodgkin Study Group developed a new regimen, PVAG (prednisone, vinblastine, doxorubicin, and gemcitabine). In this multicenter phase 2 study, elderly HL patients in early unfavorable and advanced stages received 6 to 8 cycles of PVAG and additional radiotherapy if they were not in complete remission (CR) after chemotherapy. Endpoints included feasibility, acute toxicity, and response rate. Fifty-nine patients 60 to 75 years of age (median, 68 years) were eligible for analysis; 93% had advanced stage disease. WHO grade 3/4 toxicities were documented in 43 patients; 46 patients responded with CR/CR uncertain (78%). Within 37 months median observation time, 15 progressions or relapses and 17 deaths were observed, of which 8 were related to HL and 1 was the result of treatment-related toxicity. The 3-year estimates for overall survival and progression-free survival were 66% (95% CI, 50%-78%) and 58% (95% CI, 43%-71%), respectively. We conclude that PVAG is safe and feasible in elderly HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00147875. (Blood. 2011;118(24):6292-6298)

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Boell, Boris UNSPECIFIED UNSPECIFIED UNSPECIFIED Bredenfeld, Henning UNSPECIFIED UNSPECIFIED UNSPECIFIED Goergen, Helen UNSPECIFIED UNSPECIFIED UNSPECIFIED Halbsguth, Teresa UNSPECIFIED UNSPECIFIED UNSPECIFIED Eich, Hans T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Soekler, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Markova, Jana UNSPECIFIED UNSPECIFIED UNSPECIFIED Keller, Ulrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Graeven, Ullrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Kremers, Stephan UNSPECIFIED UNSPECIFIED UNSPECIFIED Geissler, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Trenn, Guido UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichenauer, Dennis A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-483583
DOI:	10.1182/blood-2011-07-368167
Journal or Publication Title:	Blood
Volume:	118
Number:	24
Page Range:	S. 6292 - 6299
Date:	2011
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1528-0020
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OLDER PATIENTS; DISEASE; AGE; CHEMOTHERAPY; REGIMEN; CYCLOPHOSPHAMIDE; PROCARBAZINE; VINCRISTINE; INTENSITY; BLEOMYCIN Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/48358